Your Health, We Care
Enasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDAapproved test.
FDA,2023.12
August 1, 2017 -- The U.S. Food and Drug Administration today approved Enasideni···【more】
Release date：2026-03-10Recommended：7
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that sy···【more】
Release date：2026-03-10Recommended：8
Enasidenib is suitable for Leukemia.【more】
Release date：2026-01-06Recommended：43
Encidipine is a new type of drug that has attracted a lot of attention in the me···【more】
Release date：2024-12-26Recommended：259
